BioNotebook: Ten deals and a breakup; Gilead/Ono, Vernalis/Novartis, Sorrento/NantWorks and more
This article was originally published in Scrip
Gilead licenses Ono BTK Inhibitor; Novartis stops developing Vernalis drug; Sorrento partners with NantWorks, Conkwest; Xencor, Novo enter discovery collaboration; ContraVir licenses Chimerix antiviral; MiNa accesses Marina technology; Bayer takes second X-Chem program; Durect grants rights to Santen; Adapt licenses Lightlake's intranasal treatment; and Oncothyreon expands deal with Array.
You may also be interested in...
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.